⚠ Evidence warning: Clinical trials or other evidence do not support the claims that a 6-week gluten challenge at 3 g a day finds about 90% of cases, that one question prevents 90% of mis-ordered panels, that several named countries routinely skip biopsy in adults, that blood tests catch most dietary slips, and the rankings of the most common testing mistakes. This page keeps it as a report of what people, websites or other media say.

Celiac Serology Testing: tTG, DGP, EMA, and the Traps

Celiac Serology Testing tTG DGP EMA — scientific infographic poster

Table of Contents

  1. Why Getting the Order Right Matters
  2. Step One: Total Immunoglobulin A Is Checked First
  3. tTG-IgA — The Primary Screen
  4. EMA-IgA — The Confirmatory Test
  5. DGP-IgA and DGP-IgG — The Specialists' Test
  6. Why the Old AGA Test Is Outdated
  7. Titer Magnitude: When Numbers Replace Biopsy
  8. The Critical Trap: Tests Need Gluten in the Diet
  9. Gluten Challenge Protocols
  10. Seronegative Celiac — When Blood Tests Miss It
  11. Post-Diagnosis: Using tTG to Track Healing
  12. Home and Mail-In Test Kits
  13. Insurance, Coding, and Cost
  14. Pediatric vs Adult Panels
  15. Ordering Pitfalls — What Labs Actually Run
  16. Why a Gastroenterologist Will Not Just "Test You"
  17. Key Research Papers
  18. Connections
  19. Featured Videos

Why Getting the Order Right Matters

Celiac disease is one of the most under-diagnosed autoimmune conditions in medicine. Roughly 1% of the population has it, but most walk around undiagnosed for years — some for decades. The reason is almost never that the blood tests are bad. The tests are excellent. The reason is that the tests get ordered wrong, run wrong, or interpreted wrong — and that the patient often is not eating gluten when the blood is drawn, which silently destroys every result on the panel.

This article is the map. It walks through every blood test used to screen for and confirm celiac disease, in the order a smart clinician (or a smart patient advocating for themselves) would use them. It flags the traps that cause false negatives, the rules that let you skip the biopsy in certain cases, and the insurance and lab-order details that decide whether your workup costs $40 or $400.

If you read one section, read The Critical Trap: Tests Need Gluten in the Diet. That single mistake — going gluten-free before testing — is the number-one reason people get told "you don't have celiac" when they actually do.

Step One: Total Immunoglobulin A Is Checked First

Before any celiac-specific antibody is ordered, a competent workup starts with a total serum immunoglobulin A (IgA) level. Here is why.

Most celiac antibodies are immunoglobulin A class antibodies — they belong to the branch of the immune system that patrols mucosal surfaces, including the lining of the gut. That is a design feature: gluten hits the gut first, so the gut's immune system responds first, and the antibodies it makes are mostly immunoglobulin A. Unfortunately, 2–3% of people with celiac disease are selective immunoglobulin A deficient, compared to roughly 0.2% of the general population. If you are in that group, your body simply cannot produce meaningful quantities of immunoglobulin A, and every immunoglobulin A-based celiac test will come back falsely negative no matter how sick your gut is.

A total immunoglobulin A measurement costs around $10–$25 and takes a single extra tube of blood. If it comes back low (typically under 7 mg/dL for adults, lower cutoffs for kids), your clinician switches to immunoglobulin G-based celiac tests: tTG-IgG and DGP-IgG. If it is normal, you proceed with the standard immunoglobulin A panel. Skipping this step is the second most common mistake in celiac testing, after drawing blood off-gluten.

tTG-IgA — The Primary Screen

Tissue transglutaminase immunoglobulin A (tTG-IgA) is the single most important celiac test. It is the first blood test every major guideline body — the American College of Gastroenterology, the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN), the British Society of Gastroenterology — recommends for anyone with suspected celiac disease. If you are going to order one test, this is it.

What it measures: tissue transglutaminase is the enzyme inside your intestinal lining that modifies gluten peptides after you eat them. In celiac disease, the immune system mistakenly starts producing antibodies against this enzyme. Those antibodies circulate in blood and are easy to detect with an ELISA assay.

Figures of 93–98% sensitivity (it catches most cases) and 96–99% specificity (it rarely lights up when celiac is absent) are often quoted for adults eating a normal gluten-containing diet. A 2022 pooled analysis of 113 studies, all in hospital or specialist settings, measured lower figures at the most commonly reported cut-offs: in adults, sensitivity 90.7% (95% confidence interval 87.3–93.2%) and specificity 87.4% (84.4–90.0%); in children, sensitivity 97.7% and specificity 70.2%. It stays the first-line screen in the guidelines above.

Known caveats:

EMA-IgA — The Confirmatory Test

Endomysial antibody immunoglobulin A (EMA-IgA) is celiac serology's gold standard for specificity. It is reported as a titer on a dilution series (1:5, 1:10, 1:20, etc.) and uses an old-school immunofluorescence assay, where a technician looks through a microscope at monkey esophagus or human umbilical cord tissue and scores the pattern of antibody binding. It is labor-intensive and operator-dependent, which is why it costs more (roughly $100–$200) and is not the first-line screen.

What it buys you is near-perfect specificity — essentially 100% in experienced labs. The same 2022 pooled analysis found IgA endomysial antibody specificity of 99.6% in adults (sensitivity 88.0%) and 93.8% in children (sensitivity 94.5%), and its authors say the high adult specificity supports using it to rule celiac disease in. A positive EMA-IgA in a symptomatic patient, with a positive tTG-IgA, is so specific for celiac that under the 2020 ESPGHAN pediatric guidelines it can replace the duodenal biopsy in carefully selected cases, and British Society of Gastroenterology interim guidance opened a no-biopsy route for some adults (see Titer Magnitude).

EMA is not used in isolation. The standard workflow is: screen with tTG-IgA, and if positive (especially if borderline), confirm with EMA-IgA on the same sample or a repeat draw.

DGP-IgA and DGP-IgG — The Specialists' Test

Deamidated gliadin peptide (DGP) antibodies target a chemically modified form of gliadin — the fragment of gluten that the enzyme tissue transglutaminase has "deamidated" inside the gut wall. Think of it as the crime scene residue: if your immune system has been reacting to gluten as processed by celiac gut chemistry, you will usually have anti-DGP antibodies in your blood.

DGP has three main uses:

DGP is not routinely better than tTG for the average adult screen. If your lab offers a "celiac panel" that runs tTG-IgA, EMA-IgA, total immunoglobulin A, and DGP-IgG all at once, that is fine — comprehensive. If your insurer only pays for one test, tTG-IgA is still the right pick.

Why the Old AGA Test Is Outdated

Older charts sometimes still list anti-gliadin antibody (AGA) — the original celiac blood test from the 1980s. It is no longer part of the standard workup. AGA targets native (unprocessed) gliadin and lights up in a wide range of conditions, including non-celiac gluten sensitivity, wheat allergy, Crohn's disease, and healthy wheat eaters with no gut disease at all. Its specificity is poor enough that modern guidelines explicitly recommend against it.

When "AGA" or "anti-gliadin immunoglobulin G/immunoglobulin A" appears on a celiac workup in 2026, the modern replacement is DGP. Many electronic health records still carry both order sets and the defaults drift.

Titer Magnitude: When Numbers Replace Biopsy

For decades, a duodenal biopsy was mandatory to confirm celiac disease. Then in 2012, ESPGHAN changed pediatric practice: children with a tTG-IgA at or above 10 times the upper limit of normal (≥10× ULN), confirmed by a positive EMA on a second blood draw, plus HLA-DQ2 or DQ8 positivity, could be diagnosed without endoscopy. The 2020 ESPGHAN update dropped the human leukocyte antigen (HLA) requirement, further simplifying the path.

During the COVID-19 pandemic, emergency interim guidance from the British Society of Gastroenterology extended a similar option to adults: a no-biopsy diagnosis became possible for selected adults with tTG-IgA ≥10× ULN and other clinical factors. Some descriptions add a positive EMA on a second sample; a 7-year hospital review of 433 people with a positive tTG-IgA found that adding EMA changed the predictions little (high titers 95% confirmed on biopsy, low titers 75%). The American College of Gastroenterology's 2023 update still states that biopsy is required in most patients and suggests a no-biopsy strategy only in selected children. The British society published new adult guidelines in Gut in July 2026; the published summary does not state their no-biopsy criteria.

The 10-times rule has been measured in adults. A study of three groups (740 specialist-clinic patients, 532 low-suspicion endoscopy patients and 145 people with raised tTG from several countries) found that 95.2% to 100% of people at or above 10× ULN had Marsh 3 gut damage. Its sensitivity was only 30% to 54%, so many people with that damage fall below 10× ULN. In Scotland, 320 of 322 adults at or above 10× ULN who had a biopsy were diagnosed with celiac disease.

Practical takeaway: if your tTG-IgA comes back at, say, 250 U/mL on an assay whose normal is under 20 U/mL, that is a 12× ULN result. Whether the biopsy-optional pathway applies differs by region. Many countries, including the UK, the Netherlands, and parts of Scandinavia, are said to routinely skip scopes in high-titer adults now. In the U.S., biopsy remains the default but a strong case can be made.

The Critical Trap: Tests Need Gluten in the Diet

This is the most important paragraph in this article. Every celiac blood test depends on an active immune reaction to gluten. If you stop eating gluten, your tTG-IgA, EMA, and DGP levels begin to fall within weeks, and over the following months they can reach normal. In a study of 260 children on a gluten-free diet, the median time to a normal tTG was 11.7 months on one lab method (ELISA) and 14.7 months on another (chemiluminescence), and higher starting levels took longer. Once levels are normal, the tests cannot distinguish you from a healthy person. A gastroenterologist who runs celiac serology on a patient who has been gluten-free for months is running a test that can come back negative whether or not the underlying disease is there.

This happens all the time. A patient feels better after going gluten-free on their own, later asks their doctor "could I have celiac?" and gets blood drawn that same week. The result comes back negative and the patient is told they just have "gluten sensitivity." Months or years later, symptoms return, damage accumulates in the small intestine, and the real diagnosis is missed — sometimes until a vitamin deficiency or osteoporosis forces the question open again.

Because the antibodies fall once gluten stops, testing after going gluten-free can miss the disease; the tests are built for people eating gluten. For someone already gluten-free who wants testing, two choices are described: accepting that the blood work will be uninformative, or doing a gluten challenge to reactivate the antibody response.

Gluten Challenge Protocols

A gluten challenge means eating gluten deliberately, at a meaningful dose, for a defined period so that celiac serology can detect the disease if it is present. The traditional protocol, validated in research settings and still used by most U.S. academic centers:

That is a brutal protocol for someone whose symptoms go away on a gluten-free diet. More recent studies have looked at whether shorter, lower-dose challenges can still trigger detectable antibody and histologic changes. Two reduced protocols now appear in the literature:

Dose may matter for what a two-week biopsy shows. In a small 2021 randomized trial of 14 adults with celiac disease, the fall in the villous height to crypt depth ratio after 14 days was significant at 10 g of gluten a day but not at 3 g, while symptoms and blood interleukin-2 rose at both doses (significantly or nearly so). The 20-adult study above saw no difference between 3 g and 7.5 g.

If you cannot tolerate a full challenge (some patients get so sick they abandon it), a short challenge followed by both serology and biopsy is still better than nothing — and human leukocyte antigen genetic testing can help: if you are negative for HLA-DQ2 and DQ8, celiac disease is essentially ruled out without any gluten at all (see the human leukocyte antigen genetic testing article).

Seronegative Celiac — When Blood Tests Miss It

Roughly 5–10% of adults with biopsy-proven celiac disease have negative or borderline serology despite eating gluten. The Marsh lesions are there. The villi are blunted. The tTG is stubbornly under the cutoff.

Much is not known. A 2024 review says data on how common seronegative celiac is, its features and its outcome are inconclusive, because few studies exist and few patients have been diagnosed. The same review says it can be suspected with flat villi, positive HLA-DQ2 and/or HLA-DQ8 and no celiac antibodies; once other causes are ruled out, the diagnosis can be confirmed by clinical and biopsy improvement after 1 year on a gluten-free diet.

Why this happens is not fully understood. Some patients have very localized, low-grade disease. Some have mild immunoglobulin A deficiency that falls inside the "normal" range but low enough to suppress tTG-IgA. Some have partially treated celiac from inadvertently reduced-gluten diets before testing.

The practical implication: a negative blood test in a high-suspicion patient is not the end of the workup. If you have iron-deficiency anemia that will not respond to oral iron, unexplained elevated liver enzymes, a first-degree relative with celiac, type 1 diabetes, Hashimoto's thyroiditis, osteoporosis before age 50, or dermatitis herpetiformis, a referral for endoscopic biopsy is appropriate regardless of blood results. See the biopsy and Marsh classification article for what the procedure finds.

Post-Diagnosis: Using tTG to Track Healing

Once you are diagnosed and start a strict gluten-free diet, tTG-IgA becomes one of the cheapest and most useful follow-up tools in medicine. Antibody levels are commonly described as roughly halving every six months and normalizing within 12 to 24 months in most patients on a truly gluten-free diet. Measured times depend on the lab method: among 260 children, the median time to normal was 11.7 months by ELISA and 14.7 months by chemiluminescence, with 86% and 70% normal at 30 months, and older age at diagnosis and higher starting levels meant longer times.

What that means in practice:

Most guidelines recommend tTG-IgA retesting at 6 months, 12 months, and annually thereafter. It does not replace a follow-up endoscopy in complicated cases — villous atrophy can persist even when antibodies normalize — but it is described as catching the majority of dietary slips cheaply. Blood tests are weak at finding ongoing gut damage: a 2017 pooled analysis of 26 studies of people on a gluten-free diet found that tTG-IgA picked up only about half of those with persistent villous atrophy (sensitivity 0.50; EMA-IgA 0.45), with specificity of 0.83 and 0.91.

Home and Mail-In Test Kits

Several direct-to-consumer companies now sell celiac serology by mail. You order online, receive a finger-prick or mail-in venous kit, and get results back in one to two weeks. Typical price: $70–$150.

Known caveats of these kits:

Home kits are most useful as a screening nudge — "am I in the neighborhood?" — for people whose insurance hassles them about ordering the lab traditionally. They are not a substitute for a proper workup.

Insurance, Coding, and Cost

In the United States, a standard celiac panel (total immunoglobulin A + tTG-IgA, sometimes with EMA reflex) runs about $40–$120 at a large reference laboratory on a commercial insurance plan, and commonly costs nothing out-of-pocket when ordered with a documented clinical indication. Relevant CPT codes include 82784 (total immunoglobulin A), 83516 or 86364 (tTG-IgA), 86255/86256 (EMA titer), and 83516 (DGP variants).

Indications written on the order include "chronic diarrhea," "iron deficiency anemia," "unexplained weight loss," "family history of celiac disease," or "autoimmune thyroid disease" — all recognized indications that meet medical-necessity criteria.

Without insurance, a cash-pay tTG at a direct-to-consumer lab service runs about $30–$60 — often cheaper than a home kit and including a real draw. This is one path open to uninsured patients.

Pediatric vs Adult Panels

Pediatric and adult panels overlap but are not identical.

Pediatric gastroenterology practices tend to be more aggressive about testing first-degree relatives, particularly siblings, because early detection changes growth trajectory and bone density outcomes. Parents of a diagnosed child can expect their other children to be offered testing over the next several years.

Ordering Pitfalls — What Labs Actually Run

A "celiac panel" means different things at different labs. Common variations you may see:

Some patients ask their gastroenterologist or primary care physician directly: "Are you ordering tTG-IgA, total immunoglobulin A, and DGP-IgG? And EMA if tTG is positive?" That five-second clarification is said to prevent 90% of mis-ordered panels.

Some electronic health record systems have a default "Celiac Screen" order that includes only tTG-IgA, no total immunoglobulin A, and no DGP. That is not wrong, but it is not ideal — especially for a first workup.

Why a Gastroenterologist Will Not Just "Test You"

Patients frequently walk into a gastroenterologist's office saying "I've been gluten-free for a year and I want to know if I have celiac. Can you just test me?" The answer, almost always, is no — not usefully. Here is what the gastroenterologist hears and why they push back:

The realistic options, if you are already gluten-free and want a definitive answer:

A good gastroenterologist will lay out all three paths and let you choose. When one refuses to test but gives no reason, the reasoning above is usually what lies behind it.

Key Research Papers

Peer-reviewed work on celiac antibody assay performance, the no-biopsy pathway, immunoglobulin A-deficiency workarounds, HLA-DQ2/DQ8 typing, and the histopathology that serology is meant to predict.

  1. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease. American Journal of Gastroenterology. 2013;108(5):656-676. — doi:10.1038/ajg.2013.79
  2. Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. Journal of Pediatric Gastroenterology and Nutrition. 2020;70(1):141-156. — doi:10.1097/MPG.0000000000002497
  3. Lebwohl B, Sanders DS, Green PHR. Coeliac Disease. Lancet. 2018;391(10115):70-81. — doi:10.1016/S0140-6736(17)31796-8
  4. Singh P, Arora A, Strand TA, et al. Global Prevalence of Celiac Disease: Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. 2018;16(6):823-836.e2. — doi:10.1016/j.cgh.2017.06.037
  5. Werkstetter KJ, Korponay-Szabó IR, Popp A, et al. Accuracy in Diagnosis of Celiac Disease without Biopsies in Clinical Practice. Gastroenterology. 2017;153(4):924-935. — doi:10.1053/j.gastro.2017.06.002
  6. Tonutti E, Bizzaro N. Diagnosis and Classification of Celiac Disease and Gluten Sensitivity. Autoimmunity Reviews. 2014;13(4-5):472-476. — doi:10.1016/j.autrev.2014.01.043
  7. Lewis NR, Scott BB. Meta-Analysis: Deamidated Gliadin Peptide Antibody and Tissue Transglutaminase Antibody Compared as Screening Tests for Coeliac Disease. Alimentary Pharmacology & Therapeutics. 2010;31(1):73-81. — doi:10.1111/j.1365-2036.2009.04110.x
  8. Sblattero D, Berti I, Trevisiol C, et al. Human Recombinant Tissue Transglutaminase ELISA: An Innovative Diagnostic Assay for Celiac Disease. American Journal of Gastroenterology. 2000;95(5):1253-1257. — doi:10.1111/j.1572-0241.2000.02018.x
  9. Volta U, Granito A, Parisi C, et al. Deamidated Gliadin Peptide Antibodies as a Routine Test for Celiac Disease: A Prospective Analysis. Journal of Clinical Gastroenterology. 2010;44(3):186-190. — doi:10.1097/MCG.0b013e3181c378f6
  10. Megiorni F, Pizzuti A. HLA-DQA1 and HLA-DQB1 in Celiac Disease Predisposition: Practical Implications of the HLA Molecular Typing. Journal of Biomedical Science. 2012;19(1):88. — doi:10.1186/1423-0127-19-88
  11. Marsh MN. Gluten, Major Histocompatibility Complex, and the Small Intestine: A Molecular and Immunobiologic Approach to the Spectrum of Gluten Sensitivity. Gastroenterology. 1992;102(1):330-354. — doi:10.1016/0016-5085(92)91819-P
  12. Oberhuber G, Granditsch G, Vogelsang H. The Histopathology of Coeliac Disease: Time for a Standardized Report Scheme for Pathologists. European Journal of Gastroenterology & Hepatology. 1999;11(10):1185-1194. — doi:10.1097/00042737-199910000-00019
  13. Schyum AC, Rumessen JJ. Serological Testing for Celiac Disease in Adults. United European Gastroenterology Journal. 2013;1(5):319-325. — doi:10.1177/2050640613502788
  14. Caio G, Volta U, Sapone A, et al. Celiac Disease: A Comprehensive Current Review. BMC Medicine. 2019;17(1):142. — doi:10.1186/s12916-019-1380-z
  15. Rubio-Tapia A, Hill ID, Semrad C, et al. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. American Journal of Gastroenterology. 2023;118(1):59-76. — PubMed PMID: 36602836
  16. Penny HA, Shiha MG, Raju SA, et al. The 2026 British Society of Gastroenterology guidelines on the diagnosis and management of adult coeliac disease. Gut. 2026 (online ahead of print). — PubMed PMID: 42437688
  17. Sheppard AL, Elwenspoek MMC, Scott LJ, et al. Systematic review with meta-analysis: the accuracy of serological tests to support the diagnosis of coeliac disease. Alimentary Pharmacology & Therapeutics. 2022;55(5):514-527. — PubMed PMID: 35043426
  18. Penny HA, Raju SA, Lau MS, et al. Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts. Gut. 2021;70(5):876-883. — PubMed PMID: 33139268
  19. Johnston RD, Chan YJ, Mubashar T, et al. No-biopsy pathway following the interim BSG guidance reliably diagnoses adult coeliac disease. Frontline Gastroenterology. 2022;13(1):73-76. — PubMed PMID: 34966534
  20. Hoyle A, Gillett P, Gillett HR, et al. No-biopsy strategy for coeliac disease is applicable in adult patients: a 'real-world' Scottish experience. Frontline Gastroenterology. 2023;14(2):97-102. — PubMed PMID: 36818788
  21. Leffler D, Schuppan D, Pallav K, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut. 2013;62(7):996-1004. — PubMed PMID: 22619366
  22. Leonard MM, Silvester JA, Leffler D, et al. Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial. Gastroenterology. 2021;160(3):720-733.e8. — PubMed PMID: 33130104
  23. Sansotta N, Alessio MG, Norsa L, et al. Trend of Antitissue Transglutaminase Antibody Normalization in Children With Celiac Disease Started on Gluten-free Diet: A Comparative Study Between Chemiluminescence and ELISA Serum Assays. Journal of Pediatric Gastroenterology and Nutrition. 2020;70(1):37-41. — PubMed PMID: 31599818
  24. Silvester JA, Kurada S, Szwajcer A, et al. Tests for Serum Transglutaminase and Endomysial Antibodies Do Not Detect Most Patients With Celiac Disease and Persistent Villous Atrophy on Gluten-free Diets: a Meta-analysis. Gastroenterology. 2017;153(3):689-701.e1. — PubMed PMID: 28545781
  25. Volta U, Rostami K, Auricchio R, Lundin KEA. Diagnosis of Seronegative and Ultrashort Celiac Disease. Gastroenterology. 2024;167(1):104-115. — PubMed PMID: 38286391

PubMed Topic Searches

Live PubMed queries that update as new papers are indexed.

  1. PubMed: TTG-IgA sensitivity and specificity for celiac disease
  2. PubMed: Endomysial antibody testing in celiac disease
  3. PubMed: Deamidated gliadin peptide (DGP) antibodies
  4. PubMed: IgA deficiency and celiac disease screening
  5. PubMed: Gluten challenge protocols and short-course challenges
  6. PubMed: Seronegative celiac disease
  7. PubMed: TTG follow-up and gluten-free diet adherence
  8. PubMed: ESPGHAN no-biopsy pathway and high-titer tTG

Back to Table of Contents

Connections

Back to Table of Contents